Prostate cancer is a major clinical challenge, with an incidence of some 134 000 new cases in the USA in 1994 and an expected overall annual mortality of 38 000 in that country alone. Progression of the disease is unpredictable, but 5 year survival rates for those with metastatic disease are low (Coffey, 1993) . The mainstay of therapy remains removal of androgenic drive whether by orchidectomy or by pharmacological intervention (Chiarodo, 1991) . The role of radical prostatectomy remains controversial. Clinical management is facilitated by the availability of diagnostic tests for prostatic acid phosphatase (PAP) and prostate-specific antigen (PSA) . PSA is particularly useful in that it correlates to some extent with tumour burden and provides a relatively sensitive marker of response to surgery, radiotherapy or androgen ablation therapy in prostate cancer patients. It is also a sensitive indicator of disease relapse. Both PAP and PSA are secreted proteins detectable in the serum.
Recently an additional prostate-specific marker has been described (Horoszewicz et al., 1987) . This protein has been termed prostate-specific membrane antigen (PSM). It was originally defined by using the human prostate cancer cell line LNCaP (which was originally derived from a metastatic lymph node) as an immunogen to generate mouse monoclonal antibodies (Horoszewicz et al., 1983) . One such antibody, designated 7Ell-C5 or Cyt-356, binds strongly to the membranes of LNCaP cells (Lopes et al., 1990) . This antibody was used to immunoprecipitate PSM from LNCaP cells. Peptide microsequencing allowed a cDNA clone to be obtained (Israeli et al.. 1993) . The cDNA clone encodes a protein of 750 amino acids with a predicted molecular weight of 84 000. The protein is glycosylated in vivo with an apparent molecular weight of 100.5 kDa on Western blotting (Abdel-Nabi et al.. 1992) . It is thought that the epitope recognised by the Cyt-356 antibody includes a carbohydrate portion of the PSM (Troyer et al., 1993 (Troyer et al., , 1994 . It might be argued that an antibody recognising only PSM protein epitopes would be ideal for potential clinical applications in that it would avoid the possibility of cross-reactivity with similar carbohydrate side chains on unrelated proteins.
PSM is a type II membrane protein with a short cytoplasmic N-terminal region, a 24 amino acid transmembrane domain and a 707 amino acid extracellular C-terminal portion. A 149 amino acid domain in the extracellular portion of the molecular (residues 418-567) demonstrates strong homology with the human transferrin receptor (Keer et al., 1990; Rossi and Zetter, 1992) . The significance of this remains unclear. Most type II membrane antigens are either transport proteins, membrane-associated proteases or binding proteins (Parks and Lamb, 1991) . PSM is expressed in primary and metastatic prostatic tumour tissue and to some extent in normal prostate epithelium. Only low levels of the antigen are apparently expressed in benign prostatic hypertrophy (Israeli et al., 1994) .
In view of the potential diagnostic (Lopes et al., 1990; Wynant et al., 1991; Rochon et al., 1994) Microscopy was performed using a Zeiss Axioskop fluorescence microscope coupled to a CCD camera and image analysis system (Applied Imaging International).
In situ PCR (PRIVNS) PRINS was performed essentially according to the method of Koch et al. (1993) as follows. Metaphase spreads, prepared as previously described. were used directly after fixation without further pretreatment. The reaction mixture, preheated to 95'C for 5 mmn before use, contained 4 jig each of pnrmer IA and lB, 2.5 mM magnesium chloride. dATP, dCTP. dGTP to a final concentration of 0.2mM each and digoxigenin-11-dUTP (Boehringer) to a final concentration of 0.1 mM.
Immediately before transferring the reaction mixture to a prewarmed (95°C, 10 mmn) coverslip, I unit of Taq DNA polymerase was added. A preheated slide (95C, 10 mmn) was lowered onto the coverslip and, after inverting, the coverslip was sealed with rubber cement. The slide was then incubated in a moist chamber at 70'C for 3 h, after which time the reaction was stopped by washing for 2 min at 70'C in 50 mm sodium chloride, 50 mm EDTA. pH 8.0. Further processing was as described for the standard FISH procedure, the detection reagent used being anti-digoxigenin-rhodamine Fab fragments (Boehringer).
Microscopy and image analysis were as previously described.
Results

Chromosome localisation
The results of PCR analysis of the NIGMS mapping panel number 2 by PCR are illustrated in Figure 1 Figure 2 . Figure 3 shows Figure 3) . This confirms the localisation of PSM to the region llqll-llpll.2 (see Figure 2) . In view of subsequent FISH data suggesting a second locus close to 1 1q13. obtained from total human genomic DNA. YAC 1 3BE6 contains a human insert of 500 kb on pulsed-field gel electrophoresis (data not shown).
Fluorescence in situ hvbridisation
The results of fluorescent in situ hvbridisation (FISH) analysis (Pinkel et al.. 1986 : Landegent et al.. 1987 ) using YAC 13BE6 on metaphase spreads are shown in Figure 5 . Two distinct signals are apparent. One is positioned just above the centromere on the short arm of chromosome 11.
The other is approximately one-third of the way down the long arm of chromosome 11 in the 1 1q13.5 region. Given the relatively small size of the PSM gene (less than 10 kb in total. unpublished results and Heston. 1994) and the large size of the YAC insert, it is possible that the homology between these two genetic loci extends beyond the PSM gene itself.
PRINS anal!ysis
The results of in situ PCR amplification of the PSM gene are illustrated in Figure 6 (Koch et al.. 1993; Long et al., 1993) .
In these experiments, a signal was consistently observed above the centromere of chromosome 11 on the short arm. This result is consistent with PCR sublocalisation studies and suggests that the location of the known PSM gene itself is in fact on human chromosome 11 between 1 Icen and 11 p12, most probably at llpll.2.
Discussion
The expression profile of PSM has been studied previously in some detail (Israeli et al.. 1994 (Israeli et al., 1993) . Although the 129 bp cDNA PCR fragment used as a probe contains the whole of the PSM transmembrane domain, half of the probe is constituted by the sequence encoding the cytosolic 19 amino acid residues, and this sequence is likely to be unique. Furthermore, the YAC 13BE6 will contain the 450 bp segment of the PSM gene which shows 55% homology with the human transferrin receptor mRNA (Keer et al.. 1990; Rossi and Zetter. 1992 (Isaacs and Carter. 1991 A number of growth factors and their receptors are expressed by prostate tumour epithelial cells. These include both transforming growth factor alpha (TGF-x) and the epidermal growth factor (EGF) receptor. Both EGF and TGF-a increase the expression of PSM mRNA by some 8-fold in LNCaP cells in culture in androgen-depleted medium (Heston. 1994) . Again. this is in contrast to the expression of PSA induced by these grow-th factors. which is markedlv down-regulated. Tumour necrosis factor (TNF-x) and TNF-P both caused an 8-fold reduction in PSM messenger RNA levels. It is known that TGF-a is mitogenic for aggressive prostatic cancer as well as normal prostatic epithelium. Given that these experiments were conducted on LNCaP cells. all of these effects on expression levels refer to the full-length PSM mRNA and not to PSM'. Normal prostatic epithelium does not express basic fibroblast growth factor (bFGF) or the bFGF receptor. This is in contrast to the situation in prostatic cancer cells, which usually express both of these species (Yan et al.. 1993 
